- Home
- AVIR vs LPRO Comparison
AVIR vs LPRO Comparison
Compare AVIR & LPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- LPRO
- Stock Information
- Founded
- AVIR 2012
- LPRO 2000
- Country
- AVIR United States
- LPRO United States
- Employees
- AVIR N/A
- LPRO N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- LPRO Finance: Consumer Services
- Sector
- AVIR Health Care
- LPRO Finance
- Exchange
- AVIR Nasdaq
- LPRO Nasdaq
- Market Cap
- AVIR 290.4M
- LPRO 252.9M
- IPO Year
- AVIR 2020
- LPRO N/A
- Fundamental
- Price
- AVIR $2.97
- LPRO $2.26
- Analyst Decision
- AVIR Hold
- LPRO Buy
- Analyst Count
- AVIR 1
- LPRO 6
- Target Price
- AVIR $6.00
- LPRO $3.00
- AVG Volume (30 Days)
- AVIR 223.7K
- LPRO 557.8K
- Earning Date
- AVIR 11-06-2025
- LPRO 11-06-2025
- Dividend Yield
- AVIR N/A
- LPRO N/A
- EPS Growth
- AVIR N/A
- LPRO N/A
- EPS
- AVIR N/A
- LPRO N/A
- Revenue
- AVIR N/A
- LPRO $16,254,999.00
- Revenue This Year
- AVIR N/A
- LPRO $311.24
- Revenue Next Year
- AVIR N/A
- LPRO $13.17
- P/E Ratio
- AVIR N/A
- LPRO N/A
- Revenue Growth
- AVIR N/A
- LPRO N/A
- 52 Week Low
- AVIR $2.46
- LPRO $0.70
- 52 Week High
- AVIR $4.10
- LPRO $6.92
- Technical
- Relative Strength Index (RSI)
- AVIR 33.48
- LPRO 55.11
- Support Level
- AVIR $2.84
- LPRO $2.06
- Resistance Level
- AVIR $3.33
- LPRO $2.34
- Average True Range (ATR)
- AVIR 0.14
- LPRO 0.13
- MACD
- AVIR -0.04
- LPRO 0.01
- Stochastic Oscillator
- AVIR 18.98
- LPRO 75.76
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.